LONDON, May 28 (Reuters) - Shares in GlaxoSmithKline fell 1.2 percent in early trading on Wednesday, following newsthat Britain's Serious Fraud Office had opened a criminalinvestigation into the drugmaker's commercial practices. (Reporting by Ben Hirschler)
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more